Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eye-Opening Phase III Data For AbbVie’s HCV Combo Suggest A Tightened Race

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

AbbVie anticipates filing its oral three-drug combination for hepatitis C early in the second quarter after unveiling impressive top-line Phase III data. The Abbott Laboratories spinout said its late-stage pipeline positions the company for strong growth starting in 2015.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005652

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel